Epicutaneous Immunotherapy Research Launched

PR-Mount Sinai_DBV-Collaboration- VF (3)

I was just reading that DBV Technologies, out of France, has partnered with Mount Sinai Hospital, in New York, to conduct a new study to determine if food allergies can be treated with Viaskin®, an epicutaneous immunotherapy “skin patch” (EPIT®) to build immune tolerance to food antigens. The study will take place during an 18 month trial period, and the mission is two fold.

1. A first study will be focused on the EPIT® method as a treatment of food-induced ANAPHYLAXIS in mice, COMPARED TO ORAL IMMUNOTHERAPY (OIT).

2.) A second study will address the mechanism of TOLERANCE
INDUCTION, particularly the importance of the skin immune milieu and mechanism of regulatory T cells induction in the development of tolerance.

“BAGNEUX, FRANCE, 7 May 2013 – DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergies, announced today a partnership with the Jaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai (New York) for research related to the mechanism by which epicutaneous immunotherapy (EPIT®) using Viaskin® leads to immune tolerance to food antigen.”

Tags: Anaphylaxis, Research, skin patch desensitizing

Posted in Experimental, Food Challenges, Research